MicroRNA-7 as a potential therapeutic target for aberrant NF-κB-driven distant metastasis of gastric cancer

Ye, Tingbo; Yang, Meihua; Huang, Daochao; Wang, Xin; Xue, Bingqian; Tian, Na; Xu, Xiaohui; Bao, Liming; Hu, Huajian; Lv, Tiewei; Huang, Yi

doi:10.1186/s13046-019-1074-6

Cited by 85 publications

(91 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nuclear factor κB (NF‐κB) is a nuclear transcription factor which regulates expression of a large number of genes critical for the regulation of apoptosis, tumorigenesis, inflammation, and various autoimmune diseases . The NF‐κB signaling pathway is modulated by several miRNAs in certain types of cancers as previously reported . Thus, we examined whether the NF‐κB signaling pathway was regulated by miR‐148b in NSCLC.…”

Section: Introductionmentioning

confidence: 83%

MiR‐148b suppressed non‐small cell lung cancer progression via inhibiting ALCAM through the NF‐κB signaling pathway

et al. 2019

View full text Add to dashboard Cite

Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. MiRNAs are recognized as important molecules in cancer biology. The aim of the study was to identify a novel biomarker miR-148b and its mechanism in the modulation of NSCLC progression. Methods: The expressional level of miR-148b was analyzed by RT-PCR. The effect of miR-4317 on proliferation was evaluated through 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2Htetrazolium bromide (MTT) assay. The effect of miR-148b on the metastasis of NSCLC was detected through transwell assays. The verification of the target of miR-148b was assessed by TargetScan and dualluciferase reporter assay. The related proteins in this study were analyzed by western blot. Results: Our findings confirmed that miR-148b was decreased in NSCLC and NSCLC patients with lower expression exhibited poorer overall survival (OS). Increasing miR-148b significantly repressed proliferation, invasion and migration. More importantly, activated leukocyte cell adhesion molecule (ALCAM) was determined as the direct target of miR-148b, and reintroduction of ALCAM attenuated miR-148b effect on the progress of NSCLC. In addition, NF-κB signaling pathway was modulated by miR-148b/ALCAM axis. Conclusions: Our results indicated that miR-148b is able to suppress NSCLC growth and metastasis via targeting ALCAM through the NF-κB pathway. These findings provided new evidence that miR-148b serves as a potential biomarker and novel target for NSCLC treatment.

show abstract

Section: Introductionmentioning

confidence: 83%

MiR‐148b suppressed non‐small cell lung cancer progression via inhibiting ALCAM through the NF‐κB signaling pathway

et al. 2019

View full text Add to dashboard Cite

show abstract

“…To be noted, many studies indicate a tumor-suppressive role for miR-7, and its downregulation is correlated with poor prognosis in cancer patients [48][49][50]. Studies have confirmed that miR-7 can inhibit the growth of various types of cancer cells through a variety of key molecular pathways [51,52]. miR-7 also directly targets insulin-like growth factor 1 receptor (IGF1R) [53], FAK [54], and PAK1 [55], which can inhibit the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of tumor cells.…”

Section: Biomed Research Internationalmentioning

confidence: 99%

Prognostic Value of Circular RNA ciRS-7 in Various Cancers: A PRISMA-Compliant Meta-Analysis

Tian

Lin

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Circular RNAs (circRNAs) have been shown to be involved in tumorigenesis. As a member of circRNAs, ciRS-7 is thought to be a negative prognostic indicator in multiple types of cancer. The present study aimed to comprehensively explore the value of ciRS-7 in tumor malignancy. Materials and Methods. A systematic review of PubMed, Web of Science, and the Cochrane library was carried out to examine the related studies. The pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated from the available publications by STATA 12.0. Subgroup analysis, publication bias, sensitivity analysis, and meta-regression were conducted. Results. This meta-analysis included 1,714 patients from 13 cohorts. The results suggested that high ciRS-7 expression was significantly associated with overall survival (OS) (HR = 2.17, 95% CI = 1.50–3.15, P<0.001) in various cancers. Stratified analyses indicated that elevated levels of ciRS-7 appeared to be a powerful prognostic biomarker for patients with non-small-cell lung cancer (NSCLC) (HR: 2.50, 95% CI: 1.07–6.07, P=0.035), colorectal cancer (CRC) (HR: 1.95, 95% CI: 1.34–2.84, P<0.001), and gastric cancer (GC) (HR: 2.32, 95% CI: 1.48–3.64, P<0.001). A similar effect was also observed in subgroup of sample size, analysis method, and cutoff value, except for ethnicity. The increased ciRS-7 expression was associated with a higher tumor stage (OR = 2.30, 95% CI: 1.69–3.13, P<0.001). Conclusions. High expression of ciRS-7 has a significant correlation with the high stage in various cancers, and ciRS-7 is intimately associated with an adverse OS in numerous cancers. Thus, ciRS-7 may act as a potential biomarker for the development of malignancies.

show abstract

“…MiR-7, miR-9, and miR-508-3p act as tumor suppressors by inhibiting the NF-κB pathway [37,74,75]. Information regarding miR-216a is contradictory.…”

Section: Micrornas Associated With Gc Metastasis and Signaling Pathwamentioning

confidence: 99%

“…By inhibiting its target mTOR (PI3K/AKT/mTOR pathway), miR-7 induces apoptosis and suppresses tumor growth in in vivo experiments [36]. As a result of suppression of its target RELA, miR-7 inhibits the NF-κB signaling pathway and genes associated with metastasis: VNT, ICAM-1, VCAM-1, MMP-2, MMP-9, and VEGF [37].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA in Gastric Cancer Development: Mechanisms and Biomarkers

et al. 2020

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common and difficult diseases to treat. The study of signaling pathway regulation by microRNA provides information on the mechanisms of GC development and is the basis for biomarker creation. In this study, a circuit of microRNA interactions with signaling pathways was constructed. The microRNAs, associated with metastasis and chemoresistance, are described. In most cases, microRNAs in GC regulate the Wnt/β-catenin, PI3K/AKT/mTOR, RAS/RAF/ERK/MAPK, NF-kB, TGF-β, and JAK/STAT pathways. Part of the microRNA acts on several target genes that function in different pathways. This often leads to an intensification of the induced processes. MicroRNAs have also been described that have the opposite effect on different pathways, causing different functional consequences. By acting on several target genes, or genes associated with several pathways, microRNAs can function in a signaling network. MicroRNAs associated with metastasis most often interact with the Wnt/β-catenin pathway. MicroRNAs affecting chemoresistance, in most cases, affect the regulators of apoptosis and are associated with the PI3K/AKT/mTOR pathway. The characteristics of microRNAs proposed as candidates for GC biomarkers were analyzed. The currently developed diagnostic and prognostic panels of microRNAs are also considered.

show abstract

MicroRNA-7 as a potential therapeutic target for aberrant NF-κB-driven distant metastasis of gastric cancer

Cited by 85 publications

References 32 publications

MiR‐148b suppressed non‐small cell lung cancer progression via inhibiting ALCAM through the NF‐κB signaling pathway

MiR‐148b suppressed non‐small cell lung cancer progression via inhibiting ALCAM through the NF‐κB signaling pathway

Prognostic Value of Circular RNA ciRS-7 in Various Cancers: A PRISMA-Compliant Meta-Analysis

MicroRNA in Gastric Cancer Development: Mechanisms and Biomarkers

Contact Info

Product

Resources

About